drugset
drugset / Trial / NCT01359566

Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

NCT01359566 ↗

Phase 3 Completed 228 enrolled XenoPort, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).

Timeline

Start
2011-05
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Arbaclofen Placarbil Small molecule 15 mg —
Comparator Arbaclofen Placarbil Small molecule 30 mg —
Comparator Arbaclofen Placarbil Small molecule 45 mg —

Indications

multiple sclerosis